Q-omics provides the consensus-scored ITLN2 profile across patient tissues and cancer cell-line models. ITLN2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ITLN2 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, ITLN2 RNA expression shows 11,005 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LUAD, and TGCT as cancer lineages where ITLN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITLN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITLN2 survival associations across molecular data types. ITLN2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITLN2 RNA expression–survival associations across cancer types. High ITLN2 expression shows unfavorable associations in KIRP, KICH, KIRC, UCS, CHOL and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ITLN2 RNA expression.
This table summarizes ITLN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ITLN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITLN2 shows lower tumor expression in LUAD, LUSC, KIRP and KIRC and higher tumor expression in LIHC and HNSC. The LUAD box plot shows higher ITLN2 RNA expression in normal versus tumor tissue (log2 FC = −5.962, t-test p < 0.001).
This table shows molecular features associated with ITLN2 in patient tissues and cancer cell lines. In patient samples, ITLN2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ITLN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
